and primary sclerosing cholangitis (PSC). The most frequent ANA patterns in PBC sera are the 'speckled' (Figure 1), the multiple nuclear dots (MND; Figure 2), the rim-like/membranous (RL/M ...

Primary sclerosing cholangitis (PSC) is an autoimmune injury in which infiltrating ... In addition, pretreatment of PSC LDLs in vitro with neutralising TNF antibodies significantly enhanced ...

Patients on elafibranor also had stabilization in Enhanced Liver Fibrosis (ELF), a non-invasive marker of liver ... Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates ...

Once clinical suspicion has been established for primary biliary cholangitis ... antibodies. ANA -- present in up to 70% of ...

These increased levels of nebokitug corresponded with increased levels of nebokitug’s CCL24 target, reflecting effective antibody ... of patients with primary sclerosing cholangitis and down ...

Healthcare providers look to rule out other liver disorders, such as biliary obstruction, hepatitis, primary sclerosing cholangitis (a chronic inflammation of the bile ducts), and liver disease ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease ... two key biochemical markers of disease progression. Additionally, elafibranor ...

for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025 ®; EASL 2025 ...

as a first-in-class treatment for primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases. The comprehensive proteomic analyses we are presenting at EASL 2025 indicate that ...

Similar findings were seen in other biochemical liver parameters, including alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), which are important biochemical markers of ...

Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, "This new clinical data further confirms the potential of nebokitug (CM-101) as a first-in-class treatment for primary ...